Exploring the Antiviral Potential of Natural Compounds against Influenza: A Combined Computational and Experimental Approach.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Apr 2024
Historique:
received: 19 03 2024
revised: 22 04 2024
accepted: 26 04 2024
medline: 11 5 2024
pubmed: 11 5 2024
entrez: 11 5 2024
Statut: epublish

Résumé

The influenza A virus nonstructural protein 1 (NS1), which is crucial for viral replication and immune evasion, has been identified as a significant drug target with substantial potential to contribute to the fight against influenza. The emergence of drug-resistant influenza A virus strains highlights the urgent need for novel therapeutics. This study proposes a combined theoretical criterion for the virtual screening of molecular libraries to identify candidate NS1 inhibitors. By applying the criterion to the ZINC Natural Product database, followed by ligand-based virtual screening and molecular docking, we proposed the most promising candidate as a potential NS1 inhibitor. Subsequently, the selected natural compound was experimentally evaluated, revealing measurable virus replication inhibition activity in cell culture. This approach offers a promising avenue for developing novel anti-influenza agents targeting the NS1 protein.

Identifiants

pubmed: 38732151
pii: ijms25094911
doi: 10.3390/ijms25094911
pii:
doi:

Substances chimiques

Antiviral Agents 0
Biological Products 0
Viral Nonstructural Proteins 0
INS1 protein, influenza virus 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Science, Technological Development and Innovation of the Republic of Serbia
ID : 451-03-66/2024-03/200017

Auteurs

Vladimir Perovic (V)

Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, 11001 Belgrade, Serbia.

Kristina Stevanovic (K)

Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, 11001 Belgrade, Serbia.

Natalya Bukreyeva (N)

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77550, USA.

Slobodan Paessler (S)

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77550, USA.

Junki Maruyama (J)

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77550, USA.

Sergi López-Serrano (S)

Infection Biology Laboratory, Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra, Barcelona Biomedical Research Park (PRBB), 08003 Barcelona, Spain.
Institut de Recerca en Tecnologies Agroalimentaries (IRTA), Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.

Ayub Darji (A)

Institut de Recerca en Tecnologies Agroalimentaries (IRTA), Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.

Milan Sencanski (M)

Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, 11001 Belgrade, Serbia.

Draginja Radosevic (D)

Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, 11001 Belgrade, Serbia.

Simone Berardozzi (S)

Department of Chemistry and Technologies of Drugs, Sapienza University of Roma, 00185 Roma, Italy.
CLNS-Center for Life Nano Sciences@Sapienza, Istituto Italiano di Tecnologia, 00161 Roma, Italy.

Bruno Botta (B)

Department of Chemistry and Technologies of Drugs, Sapienza University of Roma, 00185 Roma, Italy.

Mattia Mori (M)

Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.

Sanja Glisic (S)

Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, 11001 Belgrade, Serbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH